PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22210719-0	2012	Dexamethasone plus octreotide regimen increases anticancer effects of docetaxel on TRAMP-C1 prostate cancer model.	Docetaxel	70-79	translocating chain-associating membrane protein 1	Mus musculus	83-88	
22210719-6	2012	CONCLUSION: Our data suggest that the neoadjuvant administration of DEX plus OCT regimen can improve the anticancer effects of DOC on the TRAMP-C1 model.	Docetaxel	127-130	translocating chain-associating membrane protein 1	Mus musculus	138-143